论文部分内容阅读
最近几年的临床试验业已证明人白血球干扰素(HuIFN—α)可用来治癌。但关于能否使用人成纤维细胞干扰素(HuIFN—β)的工作做得很少。Freuner等人最近报道了用HuIFN—β成功地治好了一例患鼻咽癌的病人。在治疗过程中,该病人的血清里出现了HuIFN—β的中和活性。本报告认为此活性是由IgG抗体而来。该项研究首次证明在同种体内存在干扰素抗原性。治疗所用的干扰素是二倍体细胞株干扰素(HuIFN—β)。这种干扰素是用聚(I·C)、环己酰亚胺与放线菌素D过度诱导而在人的包皮成纤维细胞中产生出来的。该干扰素制剂是用高氯酸和硫酸铵沉淀,然后用柱层析法与超滤法进行纯化浓缩而成。本HuIFN—β制剂的特异活性为每毫克旦白质1—2×10~6国际单位。
Clinical trials in recent years have demonstrated that human interferon-alpha (HuIFN-α) can be used to treat cancer. Little work has been done on the possibility of using human fibroblast interferon (HuIFN-β). Freuner et al. Recently reported that a patient with nasopharyngeal carcinoma was successfully treated with HuIFN-β. HuIFN-β neutralizing activity occurred in the patient’s serum during treatment. This report considers this activity is derived from IgG antibodies. This study for the first time demonstrated the presence of interferon antigenicity in the same species. Interferon for treatment is diploid cell interferon (HuIFN-β). This interferon is produced in human foreskin fibroblasts by over-induction with poly (Ic), cycloheximide and actinomycin D. The interferon preparation is precipitated with perchloric acid and ammonium sulfate and purified by column chromatography and ultrafiltration. The specific activity of the HuIFN-β preparation is 1-2 × 10 -6 International Units per mg of denatured protein.